Prescient Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Prescient Therapeutics has a total shareholder equity of A$18.1M and total debt of A$330.5K, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are A$20.4M and A$2.3M respectively.
Key information
1.8%
Debt to equity ratio
AU$330.49k
Debt
| Interest coverage ratio | n/a |
| Cash | AU$14.51m |
| Equity | AU$18.07m |
| Total liabilities | AU$2.33m |
| Total assets | AU$20.39m |
Recent financial health updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Recent updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11
Financial Position Analysis
Short Term Liabilities: PTX's short term assets (A$18.7M) exceed its short term liabilities (A$2.3M).
Long Term Liabilities: PTX's short term assets (A$18.7M) exceed its long term liabilities (A$6.2K).
Debt to Equity History and Analysis
Debt Level: PTX has more cash than its total debt.
Reducing Debt: PTX's debt to equity ratio has increased from 0% to 1.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PTX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 19.6% each year.